1. Home
  2. PVL vs BOLD Comparison

PVL vs BOLD Comparison

Compare PVL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.71

Market Cap

59.4M

Sector

Energy

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.84

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
BOLD
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
59.4M
60.8M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
PVL
BOLD
Price
$1.71
$2.84
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
44.9K
207.2K
Earning Date
03-20-2026
05-06-2026
Dividend Yield
7.43%
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.96
52 Week High
$2.04
$2.92

Technical Indicators

Market Signals
Indicator
PVL
BOLD
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
PVL
BOLD

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: